An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT
Abstract
Share and Cite
Kouroukis, C.T.; Crump, M.; MacDonald, D.; Larouche, J.F.; Stewart, D.A.; Johnston, J.; Sauvageau, S.; Beausoleil, E.; Sage, P.; Dubois, S.G.; et al. An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT. Curr. Oncol. 2015, 22, 260-271. https://doi.org/10.3747/co.22.2431
Kouroukis CT, Crump M, MacDonald D, Larouche JF, Stewart DA, Johnston J, Sauvageau S, Beausoleil E, Sage P, Dubois SG, et al. An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT. Current Oncology. 2015; 22(4):260-271. https://doi.org/10.3747/co.22.2431
Chicago/Turabian StyleKouroukis, C.T., M. Crump, D. MacDonald, J.F. Larouche, D.A. Stewart, J. Johnston, S. Sauvageau, E. Beausoleil, P. Sage, S.G. Dubois, and et al. 2015. "An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT" Current Oncology 22, no. 4: 260-271. https://doi.org/10.3747/co.22.2431